



## AMENDMENTS

### In the claims

Please amend claims 2-5 and 11-15 to read as follows:

B<sup>1</sup> 2. (Amended) The method according to claim 1, wherein said helper virus is an adenovirus.

B<sup>2</sup> 3. (Amended) The method according to claim 1, wherein said packaging cell grows at least one half as rapidly as parental-type cells that do not contain an AAV rep gene, and wherein said packaging cell when used to package rAAV vectors produces at least 100 rAAV particles/cell.

B<sup>3</sup> 4. (Amended) The method according to any of claims 1-3, wherein said mammalian cell of step (a) is prepared using a single plasmid, said plasmid comprising AAV rep gene operably linked to a heterologous promoter and AAV cap gene operably linked to a promoter, wherein p5 promoter function has been replaced by a heterologous promoter.

SUP 18 B<sup>3</sup> 5. (Amended) The method according to claim 4, wherein said heterologous promoter is a mouse metallothionein I (mMT-I) promoter.

B<sup>4</sup> 11. (Amended) The AAV packaging cell of claim 10, wherein said helper-virus-inducible expression of said stably integrated AAV rep gene is inducible by adenovirus.

12. (Amended) The AAV packaging cell of claim 10, wherein said packaging cell grows at least one half as rapidly as parental-type cells that do not contain an AAV rep gene, and

B<sup>4</sup>  
wherein said packaging cell when used to package rAAV vectors produces at least 100 rAAV particles/cell.

---

B<sup>5</sup>  
13. (Amended) The AAV packaging cell of any of claims 10-12, wherein said cell is prepared using a single plasmid, said plasmid comprising AAV rep gene operably linked to a heterologous promoter and AAV cap gene operably linked to a promoter, wherein p5 promoter function has been replaced by a heterologous promoter.

---

SUB  
CH 14. (Amended) The AAV packaging cell of claim 13, wherein said heterologous promoter is a mouse metallothionein I (mMT-I) promoter.

---

15. (Amended) The AAV packaging cell of claim 10, further comprising a stably integrated recombinant AAV (rAAV) vector, said vector comprising a polynucleotide sequence of interest located between two AAV inverted terminal repeat (ITR) regions, wherein said polynucleotide is operably linked to a promoter.

---

B<sup>6</sup>  
16. (Amended) A method of packaging a recombinant AAV vector, comprising the steps of:

(a) introducing a recombinant AAV (rAAV) vector into the AAV packaging cell of claim 10, said vector comprising a polynucleotide sequence of interest located between two AAV inverted terminal repeat (ITR) regions, wherein said polynucleotide is operably linked to a promoter;

(b) introducing a helper virus; and

(c) incubating the cell under conditions suitable for replication and packaging of AAV such that said rAAV vector is packaged.

17. (Amended) A method of packaging a recombinant AAV vector, comprising the steps of:

(a) introducing a helper virus into an AAV packaging cell of claim 15 which comprises a stably integrated rAAV vector comprising a polynucleotide of interest operably linked to a promoter; and

(b) incubating the cell under conditions suitable for replication and packaging of AAV such that said rAAV vector is packaged.

Please add new claim 23.

23. (New) The method of any of claims 16, 17, 21 or 22, wherein said AAV packaging cell is prepared using a single plasmid, said plasmid comprising AAV rep gene operably linked to a heterologous promoter and AAV cap gene operably linked to a promoter, wherein p5 promoter function has been replaced by a heterologous promoter.